In a small observational study, telitacicept use was associated with improvement in renal and hematologic parameters in patients with lupus nephritis and nephrotic syndrome. Telitacicept use is ...

On the heels of last week’s lupus nephritis nod from the FDA, Roche’s Gazyva is proving once again that it still has new ...

The randomized, open-label INSHORE trial (ClinicalTrials.gov Identifier: NCT05627557) evaluated the safety and efficacy of obinutuzumab in children and young adults in clinical remission aged 2 to 25 ...

Please provide your email address to receive an email when new articles are posted on . Early recognition of conditions such as drug-induced lupus overlapping with vasculitis is crucial. Part of ...

Positive Phase III Results For Roche's Gazyva/Gazyvaro In Children And Young Adults With Idiopathic Nephrotic Syndrome. <li /> Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more ...

Genentech, a member of Roche (RHHBY), announced statistically significant and clinically meaningful results from the Phase III INShore study of Gazyva in children and young adults with idiopathic ...

Roche (ROG: SIX) has reported positive top-line results from the Phase III INShore study of Gazyva (obinutuzumab) in children ...

Roche’s phase III INShore study of Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome meets its primary endpoints: Basel Wednesday, October 29, 2025 ...

In a small study, proteinuria improved even in patients with nephrotic syndrome and lupus nephritis. Belimumab appears similarly effective and well tolerated in patients with lupus nephritis (LN) with ...